Somatostatin prevents lipopolysaccharide-induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 1002-1008

  Bai, Lijuan ^a,b   Zhang, Xique ^a   Li, Xiaohong ^a   Liu, Na ^a   Lou, Fan ^a   Ma, Honglei ^a   Luo, Xiaoguang ^a   Ren, Yan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b People's Hospital of Liaoning Province   (China)

Author keywords

Microglia; Neuron; Parkinson's disease; Somatostatin; Substantia nigra

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SOMATOSTATIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; NEUROPROTECTIVE AGENT; NOS2 PROTEIN, RAT; PTGS2 PROTEIN, RAT; RELA PROTEIN, RAT; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROGLIA; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NISSL SUBSTANCE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PARKINSON DISEASE, SECONDARY; PATHOLOGY; SPRAGUE DAWLEY RAT; STEREOTACTIC PROCEDURE;

RATTUS;

ANIMALS; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FEMALE; INJECTIONS, INTRAVENTRICULAR; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MICROGLIA; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SOMATOSTATIN; STEREOTAXIC TECHNIQUES; SUBSTANTIA NIGRA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE;

EID: 84926626314     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3494     Document Type: Article

References (35)

1. Ramos-Moreno T, Castillo CG and Martinez-Serrano A: Long term behavioral effects of functional dopaminergic neurons generated from human neural stem cells in the rat 6-OH-DA Parkinson's disease model. Effects of forced expression of BCL-X(L). Behav Brain Res 232: 225-232, 2012.
2. Golbe LI: Young-onset Parkinson's disease: A clinical review. Neurology 41: 168-173, 1991.
3. Zanon A, Rakovic A, Blankenburg H, et al: Profiling of Parkin-binding partners using tandem affinity purification. PLoS One 8:e78648, 2013.
4. Choi SH, Joe EH, Kim SU and Jin BK: Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. J Neurosci 23: 5877-5886, 2003.
5. Song DY, Yu HN, Park CR, et al: Down-regulation of microglial activity attenuates axotomized nigral dopaminergic neuronal cell loss. BMC Neurosci 14: 112, 2013.
6. Yuan L, Wu Y, Ren X, Liu Q, Wang J and Liu X: Isoorientin attenuates lipopolysaccharide-induced pro-inflammatory responses through down-regulation of ROS-related MAPK/NF-κB signaling pathway in BV-2 microglia. Mol Cell Biochem 386: 153-165, 2014.
7. Epelbaum J, Guillou JL, Gastambide F, Hoyer D, Duron E and Viollet C: Somatostatin, Alzheimer's disease and cognition: An old story coming of age? Prog Neurobiol 89: 153-161, 2009.
8. Viollet C, Lepousez G, Loudes C, Videau C, Simon A and Epelbaum J: Somatostatinergic systems in brain: Networks and functions. Mol Cell Endocrinol 286: 75-87, 2008.
9. Epelbaum J, Ruberg M, Moyse E, Javoy-Agid F, Dubois B and Agid Y: Somatostatin and dementia in Parkinson's disease. Brain Res 278: 376-379, 1983.
10. Espino A, Calopa M, Ambrosio S, Ortolá J, Peres J and Navarro MA: CSF somatostatin increase in patients with early parkinsonian syndrome. J Neural Transm Park Dis Dement Sect 9: 189-196, 1995.
11. Tuboly G and Vécsei L: Somatostatin and cognitive function in neurodegenerative disorders. Mini Rev Med Chem 13: 34-46, 2013.
12. Chung ES, Chung YC, Bok E, et al: Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. Brain Res 1363: 143-150, 2010.
13. Chung ES, Bok E, Chung YC, Baik HH and Jin BK: Cannabinoids prevent lipopolysaccharide-induced neurodegeneration in the rat substantia nigra in vivo through inhibition of microglial activation and NADPH oxidase. Brain Res 1451: 110-116, 2012.
14. Liu M and Bing G: Lipopolysaccharide animal models for Parkinson's disease. Parkinson's Dis 2011: 327089, 2011.
15. Block ML, Zecca L and Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69, 2007.
16. Koppula S, Kumar H, Kim IS and Choi D-K: Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease. Mediators Inflamm 2012: 823902, 2012.
17. Geng Y, Fang M, Wang J, et al: Triptolide down-regulates COX-2 expression and PGE2 release by suppressing the activity of NF-κB and MAP kinases in lipopolysaccharide-treated PC12 cells. Phytother Res 26: 337-343, 2012.
18. Tansey MG and Goldberg MS: Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37: 510-518, 2010.
19. Minghetti L: Role of COX-2 in inflammatory and degenerative brain diseases. In: Inflammation in the Pathogenesis of Chronic Diseases. Vol. 42. Harris R, Bittman R, Dasgupta D, et al (eds). Springer, Netherlands, pp127-141, 2007.
20. Broom L, Marinova-Mutafchieva L, Sadeghian M, Davis JB, Medhurst AD and Dexter DT: Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease. Free Radic Biol Med 50: 633-640, 2011.
21. Aoki E, Yano R, Yokoyama H, Kato H and Araki T: Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol 86: 57-64, 2009.
22. Dexter DT and Jenner P: Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62: 132-144, 2013.
23. Kim SR, Chung ES, Bok E, et al: Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation. J Neurosci Res 88: 1537-1548, 2010.
24. Miller R, James-Kracke M, Sun G and Sun A: Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34: 55-65, 2009.
25. Shen W, Qi R, Zhang J, et al: Chlorogenic acid inhibits LPS-induced microglial activation and improves survival of dopaminergic neurons. Brain Res Bull 88: 487-494, 2012.
26. Park ES, Kim SR and Jin BK: Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress. Brain Res Bull 89: 92-96, 2012.
27. Lull M and Block ML: Microglial activation and chronic neurodegeneration. Neurotherapeutics 7: 354-365, 2010.
28. Hancock D, Martin ER, Vance JM and Scott WK: Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease. Neurogenetics 9: 249-262, 2008.
29. Li M, Dai FR, Du XP, Yang QD and Chen Y: Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease. J Mol Neurosci 48: 225-233, 2012.
30. Miller JA, Trout BR, Sullivan KA, Bialecki RA, Roberts RA and Tjalkens RB: Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-κB reporter mice prior to loss of dopaminergic neurons. J Neurosci Res 89: 406-417, 2011.
31. More SV, Kumar H, Kim IS, Song SY and Choi DK: Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm 2013: 952375, 2013.
32. Cui YQ, Jia YJ, Zhang T, Zhang QB and Wang XM: Fucoidan protects against lipopolysaccharide-induced rat neuronal damage and inhibits the production of proinflammatory mediators in primary microglia. CNS Neurosci Ther 18: 827-833, 2012.
33. Teismann P: COX-2 in the neurodegenerative process of Parkinson's disease. Biofactors 38: 395-397, 2012.
34. Phani S, Loike JD and Przedborski S: Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord 18, (Suppl 1): S207-S209, 2012.
35. Kang CH, Jayasooriya RG, Choi YH, Moon SK, Kim WJ and Kim GY: β-Ionone attenuates LPS-induced pro-inflammatory mediators such as NO, PGE2 and TNF-α in BV2 microglial cells via suppression of the NF-κB and MAPK pathway. Toxicol In Vitro 27: 782-787, 2013.